Increased Expression of AXL and c‐MET in High‐Grade Clear Cell Renal Cell Carcinoma and Its Association With VEGFR‐TKI Treatment and PD‐L1 Expression
Pathology International · 2025-08 · 75 (8) · 403-413
DOI: 10.1111/pin.70030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology International, online erschienen am 02.06.2025. Verfasst von Shuji Mikami und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Receptor Protein-Tyrosine Kinases, Proto-Oncogene Proteins c-met, Kidney Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Cabozantinib, a newly developed vascular endothelial growth factor receptor‐tyrosine kinase inhibitor (VEGFR‐TKI), is an effective treatment for advanced renal cell carcinoma (RCC). However, the molecular mechanisms responsible for the superior effectiveness of cabozantinib to other drugs remain unclear. Since cabozantinib inhibits AXL and c‐MET in addition to VEGFR, the expression of these molecules was immunohistologically examined in 110 cases of primary clear cell RCC (ccRCC) and eight of sunitinib (VEGFR‐TKI)‐treated primary ccRCC. AXL expression correlated with the primary tumor stage, while c‐MET expression correlated with distant metastasis, the histological grade, and overall survival. Furthermore, the number of programmed death‐ligand 1 (PD‐L1)‐positive tumor‐infiltrating immune cells was higher in ccRCC tissues with high c‐MET expression than in those with low c‐MET expression. The expression of AXL and c‐MET was higher in sunitinib‐treated ccRCC tissues than in untreated tissues. These results suggest that AXL and c‐MET play important roles in the progression of ccRCC and resistance to sunitinib. Furthermore, c‐MET may modify the immune microenvironment by inducing PD‐L1 expression in immune cells within RCC tissues. These molecular pathways may be related to responses to cabozantinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
- Department of Diagnostic Pathology, National Hospital Organization Saitama Hospital, Saitama, Japan.
- Department of Urology, Keio University School of Medicine, Tokyo, Japan.
ORCID-Profile: Shuji Mikami
Zitieren
APA
Mikami, S., Mizuno, R., Tanaka, N., Hakozaki, K., Takamatsu, K., & Oya, M. (2025). Increased Expression of AXL and c‐MET in High‐Grade Clear Cell Renal Cell Carcinoma and Its Association With VEGFR‐TKI Treatment and PD‐L1 Expression. Pathology International, 75(8), 403-413. https://doi.org/10.1111/pin.70030
Vancouver
Mikami S, Mizuno R, Tanaka N, Hakozaki K, Takamatsu K, Oya M. Increased Expression of AXL and c‐MET in High‐Grade Clear Cell Renal Cell Carcinoma and Its Association With VEGFR‐TKI Treatment and PD‐L1 Expression. Pathology International. 2025;75(8):403-413. doi:10.1111/pin.70030
BibTeX
@article{Mikami2025,
author = {Mikami, Shuji and Mizuno, Ryuichi and Tanaka, Nobuyuki and Hakozaki, Kyohei and Takamatsu, Kimiharu and Oya, Mototsugu},
title = {Increased Expression of AXL and c‐MET in High‐Grade Clear Cell Renal Cell Carcinoma and Its Association With VEGFR‐TKI Treatment and PD‐L1 Expression},
journal = {Pathology International},
year = {2025},
volume = {75},
number = {8},
pages = {403--413},
doi = {10.1111/pin.70030}
}
EUVIMED